CXCL13 Antagonists and Their Use for the Treatment of Inflammatory Diseases

摘要

Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNFalpha antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.